Risk-score guided estimation of absolute benefit from beta-blockers after myocardial infarction in patients without heart failure: a substudy of the BETAMI-DANBLOCK trial
Authors' conclusion
The modified TRS-2P stratified baseline risk and provided estimates of absolute beta-blocker benefit, supporting further evaluation of individualized, risk-guided treatment after MI in patients with LVEF ≥40%.
Study context
- Population
- Patients with a recent MI and LVEF ≥40%patients included in the substudy
- Participants
- 5,558 patients
- Comparison
- beta-blocker or no beta-blocker therapy, across modified TRS-2P risk strata
- Primary endpoint
- Composite of:
- All-cause mortality
- New MI
- Unplanned coronary revascularization
- Ischaemic stroke
- Heart failure
- Malignant ventricular arrhythmia
Methodological detailsrandomized to beta-blocker or no beta-blocker therapy
- Randomized to beta-blocker or no beta-blocker therapy
Primary result
As reported in the abstract
Composite of:
- All-cause mortality
- New MI
- Unplanned coronary revascularization
- Ischaemic stroke
- Heart failure
- Malignant ventricular arrhythmia
Hazard ratio
- Low risk
- 0.88
- Intermediate risk
- 0.81
- High risk
- 0.88
Further findings
Three-year absolute risk reduction (ARR) and NNT by risk stratum
- Low-risk ARR
- 1.4%
- Low-risk NNT
- 72 (95% CI 41-361)
- Intermediate-risk ARR
- 2.1%
- Intermediate-risk NNT
- 47 (95% CI 27-239)
- High-risk ARR
- 3.6%
- High-risk NNT
- 28 (95% CI 16-140)
Distribution across modified TRS-2P risk strata
- Low risk
- 38.4%
- Intermediate risk
- 52.8%
- High risk
- 8.8%
Original publication
Risk-score guided estimation of absolute benefit from beta-blockers after myocardial infarction in patients without heart failure: a substudy of the BETAMI-DANBLOCK trial. Eur Heart J Qual Care Clin Outcomes. Published 10 September 2026. doi:10.
Summarised from the published abstract; every number is checked against it